161 related articles for article (PubMed ID: 37424676)
21. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
[TBL] [Abstract][Full Text] [Related]
22. Cost-Effectiveness of Hepatitis B Testing and Vaccination of Adults Seeking Care for Sexually Transmitted Infections.
Hutton DW; Toy M; Salomon JA; Conners EE; Nelson NP; Harris AM; So S
Sex Transm Dis; 2022 Jul; 49(7):517-525. PubMed ID: 35312661
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B.
Arnold E; Yuan Y; Iloeje U; Cook G
Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
Dakin H; Sherman M; Fung S; Fidler C; Bentley A
Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
[TBL] [Abstract][Full Text] [Related]
25. Antiviral therapy for hepatitis B-related liver cancer prevention is more cost-effective than cancer screening.
Robotin MC; Kansil M; Howard K; George J; Tipper S; Dore GJ; Levy M; Penman AG
J Hepatol; 2009 May; 50(5):990-8. PubMed ID: 19303657
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients.
Yuan Y; Iloeje UH; Hay J; Saab S
J Manag Care Pharm; 2008; 14(1):21-33. PubMed ID: 18240879
[TBL] [Abstract][Full Text] [Related]
27. China's efforts to shed its title of "Leader in liver disease".
Li X; Xu WF
Drug Discov Ther; 2007 Oct; 1(2):84-5. PubMed ID: 22504391
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness analysis of antiviral therapies for hepatitis B e antigen-positive chronic hepatitis B patients in China.
Zhang C; Ke W; Gao Y; Zhou S; Liu L; Ye X; Yao Z; Yang Y
Clin Drug Investig; 2015 Mar; 35(3):197-209. PubMed ID: 25672930
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
30. [Development of Markov models for economics evaluation of strategies on hepatitis B vaccination and population-based antiviral treatment in China].
Yang PC; Zhang SX; Sun PP; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):845-851. PubMed ID: 28738454
[No Abstract] [Full Text] [Related]
31. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of antiviral therapy during late pregnancy to prevent perinatal transmission of hepatitis B virus.
Wang W; Wang J; Dang S; Zhuang G
PeerJ; 2016; 4():e1709. PubMed ID: 27042389
[TBL] [Abstract][Full Text] [Related]
33. Cost-Effectiveness of 1-Time Universal Screening for Chronic Hepatitis B Infection in Adults in the United States.
Toy M; Hutton D; Harris AM; Nelson N; Salomon JA; So S
Clin Infect Dis; 2022 Jan; 74(2):210-217. PubMed ID: 33956937
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of antiviral therapy in untreated compensated cirrhosis patient with serum HBV-DNA level < 2000 IU/mL.
Lee H; Jang S; Ahn SH; Kim BK
Hepatol Int; 2022 Apr; 16(2):294-305. PubMed ID: 35322374
[TBL] [Abstract][Full Text] [Related]
35. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data.
Crowley S; Tognarini D; Desmond P; Lees M; Saal G
J Gastroenterol Hepatol; 2002 Feb; 17(2):153-64. PubMed ID: 11966945
[TBL] [Abstract][Full Text] [Related]
36. The cost-effectiveness of universal hepatitis B screening for reaching WHO diagnosis targets in Australia by 2030.
Xiao Y; Hellard ME; Thompson AJ; Seaman C; Howell J; Scott N
Med J Aust; 2023 Mar; 218(4):168-173. PubMed ID: 36596568
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness of screening immigrants for hepatitis B.
Wong WW; Woo G; Jenny Heathcote E; Krahn M
Liver Int; 2011 Sep; 31(8):1179-90. PubMed ID: 21745300
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation.
Crossan C; Tsochatzis EA; Longworth L; Gurusamy K; Davidson B; Rodríguez-Perálvarez M; Mantzoukis K; O'Brien J; Thalassinos E; Papastergiou V; Burroughs A
Health Technol Assess; 2015 Jan; 19(9):1-409, v-vi. PubMed ID: 25633908
[TBL] [Abstract][Full Text] [Related]
39. Integrated approach for triple elimination of mother-to-child transmission of HIV, hepatitis B and syphilis is highly effective and cost-effective: an economic evaluation.
Zhang L; Tao Y; Woodring J; Rattana K; Sovannarith S; Rathavy T; Cheang K; Hossain S; Ferradini L; Deng S; Sokun C; Samnang C; Nagai M; Lo YR; Ishikawa N
Int J Epidemiol; 2019 Aug; 48(4):1327-1339. PubMed ID: 30879066
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
